OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp is positioned to capitalize on the ongoing shift from in-person to digital interactions in the healthcare sector, with projected revenue growth in the high teens to low twenties and continued margin expansion. The company's infrastructure supports a significant revenue run-rate of approximately $150 million, providing built-in operating leverage and enhancing profitability over the next few years. With a robust gross margin of 74.8% driven by favorable channel partner dynamics and a strong EBITDA increase, OptimizeRx demonstrates solid financial performance that supports its growth potential amid market challenges.

OptimizeRx Corp has revised its 2026 revenue guidance downward from a range of $118 million to $124 million to $109 million to $114 million, indicating anticipated near-term challenges that could hinder the company's growth trajectory. The company is facing significant revenue weakness, particularly in the first half of 2026, with negative growth expected in the range of 10%, primarily due to issues stemming from the "most favored nation" pricing initiative affecting large pharma clients. Additionally, contracted revenue visibility has decreased by 15-20% compared to historical levels, contributing to uncertainty and further exacerbating the negative outlook on the stock's performance.